北米の遺伝性癌検査市場 – 業界動向と2029年までの予測

北米の遺伝性癌検査市場の分析と洞察

がんは、細胞の機能を制御する遺伝子の特定の変異によって引き起こされる遺伝病であり、特に細胞の増殖と再生に影響を及ぼします。遺伝性の遺伝子変異は、すべてのがんの約5〜10％の原因です。研究者は、特定の遺伝子の変異を、特定のがんの発症を通じて人々に影響を与える50を超える遺伝性がん症候群に関連付けています。さらに、乳がん症例の約5〜10％は、親から受け継いだ遺伝子変異に関連しています。したがって、がんの有病率の増加は遺伝性がんの着実な成長を促進し、したがって遺伝性がん検査市場の成長を促進しています。さらに、非侵襲性検査方法の需要の増加と、より質の高いヘルスケアと早期診断の需要の高まりは、市場成長の大きな機会です。さらに、遺伝性がん検査中に直面する倫理的課題と市場プレーヤー間の競争の激化は、市場成長の重要な課題です。

しかし、がん診断に関する厳格な規制と検査に伴う高額な費用が市場の成長を妨げる可能性があります。

Data Bridge Market Research の分析によると、北米の遺伝性癌検査市場は、予測期間中に 13.3% の CAGR で成長し、2029 年までに 55 億 9,619 万米ドルに達すると予想されています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。

北米遺伝性癌検査市場の定義

遺伝性癌とは、遺伝的変異が受け継がれることで起こる癌のことです。特定の遺伝子の有害な変異は、癌のリスク増加と関連しています。遺伝子検査により、癌を発症する生涯リスクを推定できます。これは、遺伝子、染色体、またはタンパク質の変異を調べることで行うことができます。遺伝子検査は、いくつかの種類の癌で利用できます。これには、乳癌、卵巣癌、結腸癌、甲状腺癌、前立腺癌、膵臓癌、皮膚癌、肉腫、腎臓癌、胃癌が含まれます。多くの医学的研究により、一般的な癌の 5% から 10% が遺伝性であると考えられています。遺伝子検査は、人が有害な遺伝子変異を持っているかどうかを判断するために行われます。これらの検査は、まだ癌にかかっていない家族が、癌感受性の代替物を持っていることがわかっている家族と同じ変異を受け継いでいるかどうかを判断するのにも役立ちます。

北米の遺伝性癌検査市場の動向

このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。    

ドライバー

• 遺伝性癌の発生率上昇

がんは、細胞の制御されない増殖から生じます。がんは、細胞の成長と分裂を制御する遺伝情報（遺伝子）の有害な変化（突然変異）によって発生し、細胞が効果的に機能できなくなります。

遺伝性癌の場合、個人は片方の親から変異した成長制御遺伝子のコピーを受け継ぎ、もう一方の親から同じ遺伝子の有効なコピーを受け継ぎます。変異した遺伝子は「癌感受性遺伝子」とも呼ばれます。この癌感受性遺伝子は受け継がれるため、体内のすべての細胞に存在しますが、遺伝子の有効なコピーによって各細胞は正常に機能します。ただし、変異によって細胞内の遺伝子の機能コピーが損傷すると、細胞は成長を制御できなくなり、癌化します。したがって、癌遺伝子を受け継いだ個人は、生涯に特定の癌を発症する可能性が非常に高くなります。

Thus, rising incidences of hereditary cancer increase the demand for hereditary cancer testing and may act as a driver for the growth of the North America hereditary cancer testing market.

•  Increase In The Geriatric Population

Cancer can be a disease of aging patients. Across the globe, the geriatric population is increasing. The risk of hereditary cancer among geriatrics is much more. The rising geriatric population can result in better provision of the North America hereditary cancer testing market. It anticipated an upsurge in demand in the North America hereditary cancer testing market. An aging population is causing a redistribution of the demographic structure that will affect the future of health care. Undoubtedly, the risk of cancer increases exponentially with age.

Hereditary cancer, including its incidence and associated risk, using the world's largest complete family structure and medically confirmed cancer database, was approximately twice as high in the population aged 8-20 years born to affected parents or siblings of people who have no relatives. The risk of small bowel, testicular, thyroid, and bone cancers was five to eight times greater.

Thus, the increase in cancer incidences among the geriatric population is expected to be a driving factor for the growth of the North America hereditary cancer testing market.

Restraint

• High Cost of Hereditary Cancer Testing

Hereditary cancer testing employs highly technologically advanced products. The development of these products involves rigorous research and development by the developing player. Thus, the procedures and product cost remains high, which proportionally increases the cost of testing. Testing kits are expensive because they are incredibly resource-intensive and involve high-paid doctors, transportation, and expensive medications.

In addition, testing procedures have also been used in cancer testing. However, such procedures are very expensive and may be associated with complications and worse long-term outcomes.

Thus, the high cost of cancer testing using advanced modalities and technology products may be a major restraining factor for the growth of the North America hereditary cancer testing market.

Opportunity

• Strategic Initiatives By Market Players

The rise in the North America hereditary cancer testing market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The surge in demand for hereditary cancer treatment is significantly increasing the demand for diagnostic testing methods. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.

These strategic initiatives, such as product launches, agreements, and business expansion by the major market players, will boost the market growth and are expected to act as an opportunity for the North America hereditary cancer testing market. The strategic initiatives are expected to aid in growth and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players are expected to act as an opportunity for growth in the North America hereditary cancer testing market.

Challenge

• Ethical Challenges Faced During Hereditary Cancer Testing

During hereditary cancer genetic testing, one of the significant ethical hindrances is health professionals' lack of basic knowledge about genetic testing and their lack of confidence in interpreting familial disease patterns. The challenge for healthcare providers is to provide sufficient information to support patient decision making-and evidence to support the reasoning behind any suggestions they might make.

The lack of reimbursement creates economic barriers to care. The process of hereditary cancer risk assessment and counseling is time-consuming, and it is unclear how best to document and bill for this service. Oncologists are often forced to navigate a potentially uncertain reimbursement environment for genetic testing, with various reimbursement policies among third-party payers.

Genetic testing for hereditary cancer elevates ethical matters, which can't be resolved with patients or their family members. The various aspects of ethical, cultural, and religious nature should not be a barrier to the act of hereditary cancer testing. All of these are issues to be solved. Therefore, ethical challenges during hereditary cancer testing are expected to challenge the market growth.

Post-COVID-19 Impact on North America Hereditary Cancer Testing Market

Many industries around the world have been disadvantaged over the past 18 months. This could be due to the major disruptions that their industrial and supply chain processes are experiencing due to various precautionary measures such as shutdowns and other restrictions that the facilities around the world have been following. The same places the North America hereditary cancer testing market. Also, consumption demand has subsequently decreased as people now have more opportunities to exclude non-essential expenses from their budgets as most people's overall finances have been severely affected by the boom. These aforementioned factors can be expected to burden the revenue margin of the North America hereditary cancer testing market during the forecast period.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the transplant diagnostics market.

Recent Development

• In July 2022, Helio Genomics and its business partner, Fulgent Genetics (FLGT) has announced that the American Medical Association (AMA)  issued a new Category I Current Procedural Terminology (CPT) Proprietary Laboratory Analyses code for HelioLiver and broader adoption of advanced innovative surveillance tests for liver cancer in the U.S. This has helped the company to expand their product portfolio.

North America Hereditary Cancer Testing Market Scope

North America hereditary cancer testing market is segmented into test type, diagnosis type, technology, disease type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

BY TEST TYPE

• MULTI PANEL TEST
• SINGLE SITE GENETIC TEST

On the basis of test type, the North America hereditary cancer testing market is segmented into multi panel test and single site genetic test.

BY DIAGNOSIS TYPE

• BIOPSY
• IMAGING
• LAB TESTS

On the basis of diagnosis type, the North America hereditary cancer testing market is segmented into biopsy, imaging, and lab tests.

BY TECHNOLOGY

• SEQUENCING
• POLYMERASE CHAIN REACTION (PCR)
• MICROARRAY

On the basis of technology, the North America hereditary cancer testing market is segmented into sequencing, polymerase chain reaction (PCR), and microarray.

BY DISEASE TYPE

• HEREDITARY BREAST & OVARIAN CANCER SYNDROME
• COWDEN SYNDROME
• LYNCH SYNDROME
• HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROMES
• FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
• LI-FRAUMENI SYNDROME
• VON HIPPEL-LINDAU DISEASE
• MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROMES

On the basis of disease type, the North America hereditary cancer testing market is segmented into hereditary breast & ovarian cancer syndrome, cowden syndrome, lynch syndrome, hereditary leukemia and hematologic malignancies syndromes, familial adenomatous polyposis (FAP), li-fraumeni syndrome, vol-hippel lindau disease, multiple endocrine neoplasias (MEN) syndrome.

BY END USER

• HOSPITALS
• CLINICS
• LABORATORIES
• RADIOLOGY CENTERS 
• DIAGNOSTIC CENTERS
• OTHERS

On the basis of end user, the North America hereditary cancer testing market is segmented into hospitals, clinics, laboratories, radiology centers, diagnostic centers, and others.

BY DISTRIBUTION CHANNEL

• DIRECT TENDER
• RETAIL SALES

On the basis of distribution channel, the North America hereditary cancer testing market is segmented into direct tender, retail sales.

North America Hereditary Cancer Testing Market Regional Analysis/Insights

The North America hereditary cancer testing market is analyzed and market size information is provided test type, diagnosis type, technology, disease type, end user, and distribution channel.

The countries covered in this market report U.S., Canada and Mexico.

• In 2022, U.S. is dominating due to the presence of key market players in the largest consumer market with high GDP and due to its latest advanced technology and inventions for the diagnosis of cancer.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Hereditary Cancer Testing Market Share Analysis

North America hereditary cancer testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the North America hereditary cancer testing market.

Some of the major players operating in the North America hereditary cancer testing market are Invitae Corporation, Illumina, Inc., Natera, Inc., CENTOGENE N.V., 4baseCare, Biocartis, Fulgent Genetics, Ambry Genetics, BioReference, PerkinElmer Inc., LifeLabs, Abbott, BIO-HELIX, Cepheid, Eurofins Scientific, among others.

Research Methodology: North America Hereditary Cancer Testing Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, North America vs Regional, and Vendor Share Analysis. Please request analyst call in case of further inquiry.

SKU-69434